Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. and certain executives for alleged violations of federal securities laws [1] Summary by Relevant Sections - **Company Overview** - Baxter International, Inc. is facing legal action from Bernstein Litowitz Berger & Grossmann LLP, a law firm specializing in investor rights [1] - **Legal Action Details** - The lawsuit was filed in the U.S. District Court for the Northern District of Illinois [1] - The action is on behalf of all investors who purchased or otherwise acquired shares of Baxter [1]

Rigetti's November plunge erased October's gains and then some. Is the quantum computing stock a buy in this sudden dip?Shares of quantum computing expert Rigetti Computing (RGTI +9.04%) fell 42.2% in November 2025, according to data from S&P Global Market Intelligence. The bearish timeline included a disappointing earnings report, which erased October's 48.6% gain and then some. Rigetti's stock lost 14.2% of its value across the two-month span from Sept. 30 to Nov. 29.Rigetti's Q3 report -- a quantum leap ...

Core Insights - Snowflake Inc. reported $1.21 billion in revenue for the quarter ended October 2025, marking a year-over-year increase of 28.8% and exceeding the Zacks Consensus Estimate by 2.68% [1] - The company achieved an EPS of $0.35, which is a 75% increase from $0.20 a year ago, surpassing the consensus EPS estimate of $0.31 by 12.9% [1] Financial Performance Metrics - Remaining performance obligations stood at $7.88 billion, exceeding the average estimate of $7.46 billion from five analysts [4] - The number of customers with trailing 12-month product revenue greater than $1 million reached 688, slightly above the two-analyst average estimate of 686 [4] - Product revenue was reported at $1.16 billion, surpassing the average estimate of $1.13 billion from ten analysts, reflecting a year-over-year change of 28.7% [4] - Revenue from professional services and other sources was $54.53 million, exceeding the average estimate of $52.7 million, with a year-over-year increase of 30.4% [4] - Non-GAAP product gross profit was $879.17 million, below the average estimate of $915.73 million from eight analysts [4] - GAAP product gross profit was reported at $837.57 million, exceeding the two-analyst average estimate of $798.98 million [4] Stock Performance - Over the past month, shares of Snowflake have returned -2.2%, compared to a -0.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Five Below reported a revenue of $1.04 billion for the quarter ended October 2025, reflecting a year-over-year increase of 23.1% [1] - The company's EPS was $0.68, up from $0.42 in the same quarter last year, indicating a significant improvement [1] - Revenue exceeded the Zacks Consensus Estimate of $969.89 million by 7.05%, while EPS surpassed the consensus estimate of $0.22 by 209.09% [1] Performance Metrics - Comparable sales growth was 14.3%, significantly higher than the average estimate of 6.6% from seven analysts [4] - The total number of stores at the end of the period was 1,907, slightly below the average estimate of 1,908 from five analysts [4] - New store openings totaled 49, which was also below the average estimate of 50 from four analysts [4] Stock Performance - Over the past month, Five Below's shares have returned +1.6%, outperforming the Zacks S&P 500 composite, which saw a -0.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Core Insights - PVH reported revenue of $2.29 billion for the quarter ended October 2025, a year-over-year increase of 1.7% and exceeding the Zacks Consensus Estimate of $2.27 billion by 1.16% [1] - The company's EPS for the same period was $2.83, down from $3.03 a year ago, but it surpassed the consensus EPS estimate of $2.56 by 10.55% [1] Revenue Performance - Revenue by Segment: - Americas: $682.8 million, exceeding the estimated $676.19 million [4] - Asia-Pacific (APAC): $391.9 million, surpassing the estimated $382.82 million [4] - Europe, the Middle East and Africa (EMEA): $1.11 billion, above the estimated $1.09 billion [4] - Licensing: $105.7 million, below the estimated $117.48 million [4] - Revenue by Brand: - Heritage Brands: $58.4 million, below the estimated $71.33 million, representing a year-over-year decline of 3.2% [4] - Calvin Klein: $1.02 billion, exceeding the estimated $981.18 million, with a year-over-year increase of 2.4% [4] - Tommy Hilfiger: $1.22 billion, matching the estimated $1.22 billion, reflecting a year-over-year change of 1.4% [4] Stock Performance - PVH shares have returned +12.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.1% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - NovaBridge Biosciences announced new data from the expanded Phase 1 dosing study for ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, to be presented at ESMO-IO 2025 [1][2] - The study successfully extended the therapeutic window for ragistomig, demonstrating strong anti-tumor efficacy and improved tolerability, including enhanced hepatic safety [2][3] - Ragistomig aims to provide new treatment options for patients resistant to checkpoint inhibitors, a significant drug class in cancer therapy [3][5] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - The company is developing a differentiated pipeline, including ragistomig and givastomig, targeting various cancers and conditions [8][9] - Ragistomig is being developed in collaboration with ABL Bio, utilizing advanced bispecific antibody technology to minimize off-tumor toxicity [5][6] Clinical Study Details - The Phase 1 study of ragistomig is ongoing in the U.S. and South Korea, with a primary focus on defining dose-limiting toxicity and adverse event profiles [5][6] - The new dosing schedule, Q6W, has shown promising results in PD-L1 non-responders, balancing safety and sustained efficacy [6][7] - Interim results, including immunological data, are expected to be presented at the upcoming ESMO-IO meeting [6][7]

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.Connecticut-based fund Braidwell initiated a new stake in Hinge Health (HNGE 1.16%), adding 910,476 shares during the third quarter, an estimated $44.7 million position, according to a November 14 SEC filing.What HappenedAccording to a Securities and Exchange Commission (SEC) filing published November 14, Braidwell established a new position in Hinge Health (HNGE 1.16%), acquiring 910,47 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Points - Regentis Biomaterials Ltd. has announced the pricing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][3] - The ordinary shares are set to begin trading on the NYSE American under the symbol "RGNT" on December 4, 2025, with the offering expected to close around December 5, 2025 [2] - The company plans to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing for PMA submission for its product GerlinC, as well as for corporate purposes such as debt repayment [3] Company Overview - Regentis Biomaterials Ltd. focuses on regenerative medicine, specifically developing innovative tissue repair solutions to enhance patient health and quality of life [6] - The company's lead product, GelrinC, is a cell-free hydrogel designed for treating articular knee cartilage injuries and has received CE mark approval in Europe [6] - Regentis aims to commercialize GelrinC in Europe while also working towards obtaining FDA approval in the United States [6]

Group 1 - The presentation features Graham Parry from Citigroup introducing Sanofi and its CEO, Paul Hudson, at an investment community event in Miami [1] - Investors are particularly interested in Sanofi's plans regarding the Dupixent loss of exclusivity (LOE) expected in 2031 and the company's outlook post-LOE [2]